Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

[1]  Kongming Wu,et al.  Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors , 2018, Molecular cancer.

[2]  J. Waisman,et al.  Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers , 2018, Clinical and Translational Oncology.

[3]  J. Larkin,et al.  Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427. , 2018 .

[4]  M. Carleton,et al.  Phase 1b/2 study of nivolumab in combination with an anti–IL-8 monoclonal antibody, BMS-986253, in a biomarker-enriched population of patients with advanced cancer. , 2018 .

[5]  M. Robinson,et al.  ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. , 2018, The Lancet. Oncology.

[6]  E. Jaffee,et al.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.

[7]  T. Chan,et al.  Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.

[8]  Linghong Guo,et al.  Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials , 2017, Drug design, development and therapy.

[9]  J. Lunceford,et al.  IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.

[10]  L. Roskos,et al.  Abstract 5045: Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD1 monoclonal antibody, in patients with advanced malignancies , 2017 .

[11]  G. Sica,et al.  Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients , 2017, Proceedings of the National Academy of Sciences.

[12]  Jedd D. Wolchok,et al.  T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.

[13]  E. Hsueh,et al.  Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response , 2017, Biomarker Research.

[14]  B. Escudier,et al.  Nivolumab in renal cell carcinoma: latest evidence and clinical potential , 2017, Therapeutic advances in medical oncology.

[15]  E. Plimack,et al.  Effect of exogenous interferon-gamma (IFN-gamma) on peripheral blood immune markers as part of a phase I clinical trial of combined IFN-gamma with nivolumab (Nivo) in patients (pts) with select solid tumors. , 2017 .

[16]  Nicole Schechter,et al.  Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma , 2016, Diagnostic Pathology.

[17]  D. Schadendorf,et al.  Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. , 2016, The oncologist.

[18]  L. Nardo,et al.  Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. , 2016, The Journal of clinical investigation.

[19]  B. Ma,et al.  An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers , 2016, Expert opinion on drug metabolism & toxicology.

[20]  L. Chin,et al.  Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. , 2016, Cancer discovery.

[21]  Yusuke Nakamura,et al.  Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma , 2016, Oncoimmunology.

[22]  J. Hipp,et al.  Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection? , 2016, Drugs.

[23]  J. Lunceford,et al.  T-cell inflamed phenotype gene expression signatures to predict clinical benefit from pembrolizumab across multiple tumor types. , 2016 .

[24]  Junjia Zhu,et al.  Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer , 2016, Oncotarget.

[25]  P. Ross-Macdonald,et al.  Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma , 2016, Clinical Cancer Research.

[26]  J. Taube,et al.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.

[27]  J. Kolesar,et al.  Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma. , 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[28]  Dana Pe'er,et al.  PD-1 Blockade Expands Intratumoral Memory T Cells , 2016, Cancer Immunology Research.

[29]  D. McDermott,et al.  Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma , 2015, Therapeutic advances in urology.

[30]  L. Chow,et al.  Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies. , 2015 .

[31]  J. Lunceford,et al.  Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. , 2015 .

[32]  Lon Smith,et al.  Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.

[33]  R. Motzer,et al.  Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[35]  E. Lipson,et al.  Nivolumab: targeting PD-1 to bolster antitumor immunity. , 2015, Future oncology.

[36]  J. Wolchok,et al.  Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo , 2015, The Journal of Immunology.

[37]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[38]  O. Vetterlein,et al.  The S228P Mutation Prevents in Vivo and in Vitro IgG4 Fab-arm Exchange as Demonstrated using a Combination of Novel Quantitative Immunoassays and Physiological Matrix Preparation , 2015, The Journal of Biological Chemistry.

[39]  L. Galluzzi,et al.  Novel immune checkpoint blocker approved for the treatment of advanced melanoma , 2014, Oncoimmunology.

[40]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[41]  Antoni Ribas,et al.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.

[42]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[43]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[45]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[46]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[47]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[48]  H. Shim.  One target, different effects: a comparison of distinct therapeutic antibodies against the same targets , 2011, Experimental & Molecular Medicine.

[49]  G. Freeman,et al.  The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo , 2011, The Journal of Immunology.

[50]  S. Anand,et al.  B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. , 2010, Blood.

[51]  E. Bonfá,et al.  Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases , 2010, Clinical reviews in allergy & immunology.

[52]  K Dane Wittrup,et al.  Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. , 2008, Advanced drug delivery reviews.

[53]  Yong-Sung Kim,et al.  Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. , 2007, Journal of molecular biology.

[54]  G. Freeman,et al.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.

[55]  D. Getnet,et al.  Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. , 2007, Blood.

[56]  Kenneth M. Murphy,et al.  Decision making in the immune system: The lineage decisions of helper T cells , 2002, Nature Reviews Immunology.

[57]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[58]  G. Zhu,et al.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.

[59]  J. Mackintosh.  LETTERS OF DR. MACKINTOSH.: (Vide LANCET, No. 494, p. 662.) , 1833 .

[60]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..